Journal of Nanomaterials / 2015 / Article / Tab 1 / Review Article
Recent Trends in Preparation of Poly(lactide-co -glycolide) Nanoparticles by Mixing Polymeric Organic Solution with Antisolvent Table 1 Summary of processing conditions of o/w emulsion methods and major characteristics of PLGA nanoparticles.
Polymer (grade) Solvent Polymer (%) Drug D/P Size (nm) EE (%) Reference RG502H (0.16–0.24 dL/g) DCM-DMSO 2.5 Amphotericin B 5.6 154 53 [14 ] PLGA50 : 50 (40–75 kDa) EA 2 Betamethasone-17-valerate 60 281 85 [15 ] mPEG-PLGA (11 kDa) DCM 2 Bufalin 5 164 82 [16 ] RG502H (7–17 kDa) DCM 5 β -Carotene10 200∼800 1 [17 ] PLGA75 : 25 (66–107 kDa) DCM-acetone 0.1, 0.2 Celecoxib 25, 50 115∼436 31∼86 [18 ] PLGA50 : 50 (10 kDa) EA, PC 2 Coumarin-6 5 56∼306.6 41∼52 [19 ] RG 50 : 50 H (40–75 kDa) EA-DCM 2.5 Cucumin 10 162 77 [20 ] RG 503 (n/a) DCM 1.67 Cyclosporine A 20 220 90 [21 ] PLGA50 : 50 (20–23 kDa) DCM 1 Exemestane n/a 169 64 [22 ] PLGA50 : 50 (0.36∼037 dL/g) DCM 3.3 Haloperidol 2.5∼5 524 23∼37 [23 ] PLGA (n/a) DCM 2.5∼5.0 Nimesulide 5∼10 212∼289 25∼100 [24 ] RH503 (35–40 kDa) EA 1 Paclitaxel 5 121 47 [25 ] PLGA50 : 50 (25 kDa) DCM 2.5 Paclitaxel 5 318 89 [26 ] Antibody-PLGA50 : 50 (40 kDa) Chloroform 3 Paclitaxel 20 319 91 [27 ] R503H (0.32–0.44 dL/g) DCM 5 Pirfenidone 50 225 31 [28 ] PLGA50 : 50 (40–100 kDa) DCM 1.25∼5.0 Praziquantel 10∼30 243∼360 82 [29 ] mPEG-PLGA-PLL (n/a) DCM-TFE 2 Rhodamine 1 198 90 [30 ] PGA-PLGA (103.4 kDa) PC 0.1 Saquinavir 10 120∼300 77 [31 ] PLGA (n/a) DCM 1 tPA 0.1 266∼320 66∼71 [32 ] APRPG-PEG-PLA (n/a) DCM 1 Fumagillin analog 5 130 66 [33 ] PLGA85 : 15 (50–75 kDa) DCM 12.5 Voriconazole 8∼100 207∼605 8∼63 [34 ]
Note: n/a, not available, not specified. Polymer %, polymer concentration in an organic solvent; D/P, the weight ratio of drug to polymer; EE, drug encapsulation efficiency; DCM, dichloromethane; DMSO, dimethylsulfoxide; EA, ethyl acetate; TFE, trifluoroethanol; PC, propyl carbonate; tPA, tissue-type plasminogen activator.